EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study

Alice Bernard-Tessier, Iben Spanggaard, Tapio Utriainen, Minna Tanner, Kristoffer Rohrberg, Natacha Naoun, Tarja Ikonen, Pasi Pohjanjousi, Chris Garratt, Christian Poehlein, Karim Fizazi

European Journal of Cancer · 2026-11 · 248 · 117041

DOI: 10.1016/j.ejca.2026.117041 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Alice Bernard-Tessier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. Electronic address: alice.bernard-tessier@gust…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Breast Neoplasms, Steroid Synthesis Inhibitors. Die Arbeit nennt 37 Literaturangaben. Gefördert von: MSD Sharp & Dohme GmbH, Merck, Orion Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBreast NeoplasmsSteroid Synthesis InhibitorsHumansMaleAgedMiddle AgedFemaleAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Activating androgen receptor ligand-binding domain mutationsCYP11A1 inhibitionMetastatic castration-resistant prostate cancerSteroidogenesis inhibitor

Substanzen

Steroid Synthesis Inhibitors

Autor:innen und Institutionen

  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. Electronic address: alice.bernard-tessier@gustaveroussy.fr.
  • Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Department of Oncology, Tampere University Hospital (TAYS), Tampere, Finland.
  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
  • Department of Biologics, Orion Pharma, Espoo, Finland.

Förderung

  • MSD Sharp & Dohme GmbH
  • Merck
  • Orion Corporation
  • Merck Sharp and Dohme United Kingdom

Zitieren

APA

Bernard-Tessier, A., Spanggaard, I., Utriainen, T., Tanner, M., Rohrberg, K., Naoun, N., Ikonen, T., Pohjanjousi, P., Garratt, C., Poehlein, C., & Fizazi, K. (2026). Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study. European Journal of Cancer, 248, 117041. https://doi.org/10.1016/j.ejca.2026.117041

Vancouver

Bernard-Tessier A, Spanggaard I, Utriainen T, Tanner M, Rohrberg K, Naoun N, et al. Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study. European Journal of Cancer. 2026;248:117041. doi:10.1016/j.ejca.2026.117041

BibTeX
@article{BernardTessier2026,
  author = {Bernard-Tessier, Alice and Spanggaard, Iben and Utriainen, Tapio and Tanner, Minna and Rohrberg, Kristoffer and Naoun, Natacha and Ikonen, Tarja and Pohjanjousi, Pasi and Garratt, Chris and Poehlein, Christian and Fizazi, Karim},
  title = {Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117041},
  doi = {10.1016/j.ejca.2026.117041}
}
Kostenlos starten →